Brookstone Capital Management Raises Stock Holdings in GSK plc (NYSE:GSK)

Brookstone Capital Management raised its stake in GSK plc (NYSE:GSK) by 19.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,701 shares of the pharmaceutical company’s stock after purchasing an additional 5,244 shares during the period. Brookstone Capital Management’s holdings in GSK were worth $1,072,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Sunbelt Securities Inc. grew its position in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 303 shares during the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares during the last quarter. Rehmann Capital Advisory Group increased its position in shares of GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after purchasing an additional 332 shares in the last quarter. Finally, Investment Partners Asset Management Inc. lifted its holdings in shares of GSK by 2.3% during the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock valued at $636,000 after purchasing an additional 344 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

Shares of NYSE GSK opened at $33.50 on Friday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The business’s 50 day moving average price is $34.14 and its 200 day moving average price is $38.04. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a market cap of $69.42 billion, a P/E ratio of 21.75, a P/E/G ratio of 1.44 and a beta of 0.63.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.69%. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is 95.45%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GSK. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Finally, Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.